Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue Clinical Chemistry Année : 2022

Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma

Guillaume Beinse
  • Fonction : Auteur
Bruno Borghese
  • Fonction : Auteur
Marie Métairie
  • Fonction : Auteur
Pierre-Alexandre Just
  • Fonction : Auteur
Geoffroy Poulet
  • Fonction : Auteur
Simon Garinet
  • Fonction : Auteur
Beatrice Parfait
  • Fonction : Auteur
Audrey Didelot
  • Fonction : Auteur
Camille Bourreau
  • Fonction : Auteur
Natacha Agueeff
  • Fonction : Auteur
Alexandre Lavollé
  • Fonction : Auteur
Benoit Terris
  • Fonction : Auteur
Charles Chapron
  • Fonction : Auteur
François Goldwasser
  • Fonction : Auteur
Karen Leroy
  • Fonction : Auteur
Helene Blons
  • Fonction : Auteur
Pierre Laurent-Puig
  • Fonction : Auteur
Valérie Taly
Jérôme Alexandre
  • Fonction : Auteur

Résumé

BACKGROUND: No circulating biomarker is available for endometrial carcinoma (EC). We aimed to identify DNA positions universally hypermethylated in EC, and to develop a digital droplet PCR (ddPCR) assay for detection of hypermethylated circulating tumor DNA (meth-ctDNA) in plasma from patients with EC. METHODS: DNA positions hypermethylated in EC, and without unspecific hypermethylation in tissue/cell types releasing circulating cell-free DNA in plasma, were identified in silico from TCGA/Gene Expression Omnibus (GEO) data. A methylation-specific ddPCR (meth-ddPCR) assay following bisulfite conversion of DNA extracted from plasma was optimized for detection of meth-ctDNA according to dMIQE guidelines. Performances were validated on a retrospective cohort (n ¼ 78 tumors, n ¼ 30 tumor-adjacent tissues), a prospective pilot cohort (n ¼ 33 stage I-IV patients), and 55 patients/donors without cancer. RESULTS: Hypermethylation of zinc finger and SCAN domain containing 12 (ZSCAN12) and/or oxytocin (OXT) classified EC samples from multiple noncancer samples with high diagnostic specificity/sensitivity [>97%; area under the curve (AUC) ¼ 0.99; TCGA/ GEO tissues/blood samples]. These results were confirmed in the independent retrospective cohort (AUC ¼ 0.99). Meth-ddPCR showed a high analytical specificity (limit of blank ¼ 2) and sensitivity (absolute lower threshold of detection ¼ 50 pg methDNA /mL plasma). In the pilot cohort, meth-ctDNA was detected in pretreatment plasma samples from 9/11 and 5/20 patients with advanced and non-advanced EC, respectively. 2 of 9 patients had ctDNA detected after macroscopic complete surgery and experienced progression within 6 months. No healthy donors had any copy of hypermethylated DNA detected in plasma. CONCLUSIONS: Meth-ddPCR of ZSCAN12/OXT allows a highly specific and sensitive detection of ctDNA in plasma from patients with EC and appears promising for personalized approaches for these patients.
Fichier principal
Vignette du fichier
hvac020.pdf (837.93 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04301316 , version 1 (22-11-2023)

Identifiants

Citer

Guillaume Beinse, Bruno Borghese, Marie Métairie, Pierre-Alexandre Just, Geoffroy Poulet, et al.. Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. Clinical Chemistry, 2022, 68, pp.782 - 793. ⟨10.1093/clinchem/hvac020⟩. ⟨hal-04301316⟩
16 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More